All In Biotech

Drug Trial Radar · NCT05080218

COVID-19 VaccinE Response in Rheumatology Patients

The SARS-CoV-2 Vaccine Response and Safety in Rheumatology Patients and the Influence of Temporary Interruptions in Immunomodulatory Therapy

Last checked: Nov 20, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 841 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

841

Actual

Start

Nov 15, 2021

Primary completion

Apr 4, 2024

Study completion May 28, 2024

Sponsor

Lead sponsor
Jeffrey CurtisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Alabama at Birmingham; University of Nebraska; University of Pennsylvania; AbbVie; Bristol-Myers Squibb; Novartis; Eli Lilly and Company; Pfizer; Illumination Health
First posted
Oct 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. The investigators propose to recruit up to 1000- patients with autoimmune conditions who have a completed 2-dose regime of mRNA COVID-19 vaccine (\>28 days prior) and who are planning to receive an additional dose of mRNA COVID-19 vaccine (i.e., booster). Participants in this study will be men and women 18 years and older with confirmed rheumatic disease, including psoriatic arthritis (PsA), axial spondyloarthritis (SpA) and rheumatoid arthritis (RA) who express a decision to receive the mRNA vaccination booster within 30 days post enrollment. A primary objective of this study is to test the hypothesis that holding certain medications for a brief period of time around the time of COVID-19 vaccination might improve the response to the vaccine while not unduly having safety concerns with respect to the effects of their disease. During the study, participants using the immunomodulatory therapies described outlined in protocol will be randomized to temporarily hold (for 2 weeks) versus continue after they receive the COVID-19 vaccine supplemental dose. Patients who temporarily stop one of their medications for their autoimmune inflammatory disease may be at increased risk of flares of their autoimmune condition. If these occur, they are expected to occur within 2 - 4 weeks of treatment interruption. Detailed protocol outlines the hold schedules for the therapies to be randomized in this study.

Conditions

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Spondylarthritis

Interventions

  • UpadacitinibDrug

    Hold UPA x 2 weeks at time of COVID booster

  • AbataceptDrug

    Hold SQ ABA x 2 weeks at time of COVID booster

  • SecukinumabDrug

    Hold SEC x 2 weeks at time of COVID booster

  • TofacitinibDrug

    Hold TOF x 2 weeks at time of COVID booster

  • TNF InhibitorDrug

    Hold SQ TNFi x 2 weeks at time of COVID booster

  • Canakinumab InjectionDrug

    Hold CAN TNFi x 2 weeks at time of COVID booster

  • BaricitinibDrug

    Hold BAR x 2 weeks at time of COVID booster

  • IxekizumabDrug

    Hold IXE x 2 weeks at time of COVID booster

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quantitative ratio post booster vs. pre-booster of IgG against SARS-CoV-2 using electrochemiluminescent (ECL) technology against the receptor binding domain (RBD) of spike protein, stratified by treatment armTime frame: 6 weeks following COVID-19 vaccine booster

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Illumination Health/Bendcare

    Hoover, Alabama

  • Rheumatology Care Center

    Hoover, Alabama

  • Arizona Arthritis & Rheumatology Research, PLLC

    Phoenix, Arizona

  • Attune Health

    Beverly Hills, California

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • University of Pennsylvania Medical Center

    Philadelphia, Pennsylvania

  • Metroplex Clinical Research Center

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.